Effect of a long acting somatostatin analogue SMS 201-995 on jejunostomy effluents in patients with severe short bowel syndrome.

Ladefoged K, Christensen KC, Hegnhøj J, Jarnum S

Gut1 Jul 1989Cited by 75 (Europe PMC)

PMID2668129PMCIDPMC1434310DOI10.1136/gut.30.7.943PepBankPUB-02668129

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, intravenous octreotide reduced faecal mass versus placebo (p less than 0.005).
In plain wordsIn severe short bowel syndrome, intravenous octreotide reduced stool mass versus placebo.
Peptide
Octreotide
Outcome
DecreaseFaecal mass
Study
n = 6
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
25 micrograms/h · intravenous infusionAs given in this study (human).
Source sentences
Summary
Faecal mass was reduced (p less than 0.005) and intestinal net sodium absorption was increased (p less than 0.005) by intravenous infusion of SMS 25 micrograms/h.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812901
02HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, intravenous octreotide increased intestinal net sodium absorption versus placebo (p less than 0.005).
In plain wordsIn severe short bowel syndrome, intravenous octreotide increased net salt absorption versus placebo.
Peptide
Octreotide
Outcome
IncreaseNet sodium absorption
Study
n = 6
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
25 micrograms/h · intravenous infusionAs given in this study (human).
Source sentences
Summary
Faecal mass was reduced (p less than 0.005) and intestinal net sodium absorption was increased (p less than 0.005) by intravenous infusion of SMS 25 micrograms/h.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812902
03HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, intravenous octreotide did not influence net absorption of potassium, calcium, magnesium phosphate, zinc, nitrogen or fat.
In plain wordsIn severe short bowel syndrome, intravenous octreotide did not change reported nutrient and electrolyte absorption versus placebo.
Peptide
Octreotide
Outcome
No significant changeNet nutrient and electrolyte absorption
Study
n = 6
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
25 micrograms/h · intravenous infusionAs given in this study (human).
Source sentences
Summary
Net absorption of potassium, calcium, magnesium phosphate, zinc, nitrogen and fat was not influenced.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812903
04HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, the effect of subcutaneous octreotide on faecal sodium loss persisted during open follow-up.
In plain wordsIn severe short bowel syndrome, injected octreotide maintained its effect on stool salt loss compared with pretreatment.
Peptide
Octreotide
Outcome
Direction not reportedPersistent faecal sodium loss effect
Study
n = 4
Comparator
Pretreatment
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50 micrograms every 12 hours · subcutaneous · 5 to 6 monthsAs given in this study (human).
Source sentences
Summary
The effect on faecal sodium loss persisted, but in one patient faecal mass gradually increased and finally exceeded pretreatment values.
4 context sentences(design, population, supporting numbers)
Summary · context
Four patients continued with a five to six months open follow up study when subcutaneous SMS in the same dose was administered by the patients at home.
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812906
05HumanNon-randomized trialEfficacy outcome
In one patient with severe short bowel syndrome, faecal mass gradually increased during octreotide follow-up and exceeded pretreatment values.
In plain wordsIn one short bowel patient, stool mass increased during octreotide follow-up and exceeded pretreatment levels.
Peptide
Octreotide
Outcome
IncreaseFaecal mass increase in one patient
Study
n = 1
Comparator
Pretreatment
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50 micrograms every 12 hours · subcutaneous · 5 to 6 monthsAs given in this study (human).
Source sentences
Summary
The effect on faecal sodium loss persisted, but in one patient faecal mass gradually increased and finally exceeded pretreatment values.
4 context sentences(design, population, supporting numbers)
Summary · context
Four patients continued with a five to six months open follow up study when subcutaneous SMS in the same dose was administered by the patients at home.
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812907
06HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, subcutaneous octreotide had a similar effect on net sodium absorption to intravenous infusion.
In plain wordsIn severe short bowel syndrome, injected octreotide had a similar effect on net salt absorption to intravenous octreotide.
Peptide
Octreotide
Outcome
Direction not reportedNet sodium absorption with injections
Study
n: not reported in source
Comparator
Intravenous octreotide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50 micrograms every 12 hours · subcutaneousAs given in this study (human).
Source sentences
Summary
Subcutaneous injections of 50 micrograms SMS every 12 hours had a similar effect on net intestinal absorption of sodium and water.
4 context sentences(design, population, supporting numbers)
Summary · context
Faecal mass was reduced (p less than 0.005) and intestinal net sodium absorption was increased (p less than 0.005) by intravenous infusion of SMS 25 micrograms/h.
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812904
07HumanNon-randomized trialEfficacy outcome
In severe short bowel syndrome, subcutaneous octreotide had a similar effect on net water absorption to intravenous infusion.
In plain wordsIn severe short bowel syndrome, injected octreotide had a similar effect on water absorption to intravenous octreotide.
Peptide
Octreotide
Outcome
Direction not reportedNet water absorption with injections
Study
n: not reported in source
Comparator
Intravenous octreotide
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
50 micrograms every 12 hours · subcutaneousAs given in this study (human).
Source sentences
Summary
Subcutaneous injections of 50 micrograms SMS every 12 hours had a similar effect on net intestinal absorption of sodium and water.
3 context sentences(design, population, supporting numbers)
Summary · context
The effect of a long acting somatostatin analogue SMS 201-995 on stomal effluents in patients with severe short bowel syndrome was investigated in a double blind placebo controlled balance study.
Summary · context
Six patients, five with Crohn's disease and one with radiation enteropathy were studied.
Summary · context
Five patients had a jejunostomy and one an ileostomy.
Report a problemFND-0266812905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.